Despite ominous warnings and fearsome weather, Nephron Pharmaceuticals is stepping up again see more
As Hurricane Florence bears down on the Carolinas, manufacturers are stepping up to help those impacted as best they can. South Carolina-based Nephron Pharmaceuticals, with a facility in West Columbia, SC, is providing assistance to the community in a unique way.
Natural disasters can cause emergency drug shortages that can further impound the crisis. With that in mind, Nephron’s South Carolina facility is planning to remain open during the hurricane in order to guarantee a continuous supply of medications and other drugs in case of an emergency shortage.
Read the full story here as reported by Shopfloor, the exceptional blog of our friends and allies at the National Association of Manufacturers (NAM).
MUSC and Siemens Healthineers Form Strategic Partnership to Disrupt and Reshape Health Care DeliveryMUSC, Siemens Healthineers craft extraordinary agreement to advance healthcare see more
The Medical University of South Carolina and Siemens Healthineers have formed a first-of-its-kind strategic partnership with the mutual goal of advancing the quality of health care in South Carolina. The partnership will capitalize on the coupling of MUSC’s clinical care, research and education expertise with Siemens Healthineers’ engineering innovations and workflow-improvement capabilities.
“We are leveraging a longstanding relationship to reshape what we can both deliver in health care,” said David J. Cole, M.D., MUSC president. “Our nation is demanding that we address our fractured, costly and inefficient health care delivery systems. As the leading academic health sciences center in this state, MUSC’s purpose must be to drive the highest quality care for our patients at the lowest cost through commitment and partnerships. In discussions with the Siemens Healthineers team, we discovered a high degree of alignment with these concepts, and we are very excited to have them move forward with us. Our mutual goal is to not merely provide the best care possible for just our patients; we will define the new gold standard for others to follow.”
Specifically, this new agreement will focus on driving performance excellence at MUSC and generating significant clinical and value-driven innovations in focused target areas including pediatrics, cardiovascular care, radiology, and neurosciences.
“Ultimately, our goal is to enable health care providers to get better outcomes at lower cost. We will achieve that by empowering MUSC clinicians on this journey through four specific areas of focus – expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing health care,” said Dave Pacitti, president of North America for Siemens Healthineers. “These four core values of Siemens Healthineers are representative of the goals of our strategic relationship with MUSC, and we hope that the spirit of this flagship partnership will initiate a trend in value based care within the industry.”
Greenville, SC gains more accolades as a key cog in the state's emerging knowledge economy see more
Greenville and South Carolina are in the national spotlight again as among America's emerging knowledge economy destinations. SCBIO supporters Zylo Therapeutics, KIYATEC, VentureSouth and Chartspan are among the features companies in Bloomberg Businessweek's fabulous article. Read on for the full story.
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan of South Carolina Engaging Members With Telehealth OptionBlueCross BlueShield, BlueChoice HealthPlan of SC are urging patients to use telehealth see more
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan of South Carolina are urging people to consider telehealth for their next non-emergency room doctor visit. Members can use the service for behavioral health, urgent care and lactation consultation.
Both companies are advocating the option during Telehealth Awareness Week Oct. 15 – 19, 2018, the annual observance of telehealth programs and services available in communities around the state.
“Many health care visits can be conducted without being in person, such as by video,” said BlueCross Chief Medical Officer Matt Bartels, M.D. “While telehealth does not replace your relationship with your primary care physician it is a useful avenue for increasing access and convenience, which our members have told us is very important to them. Telehealth is especially useful in reducing unnecessary emergency room visits.”
Available anytime on a computer, tablet or mobile phone, Blue CareOnDemand— the BlueCross and BlueChoice telehealth platform — uses video to securely connect members with a physician who will review their symptoms, ask and answer questions, make diagnoses and prescribe medications, if appropriate. All the providers are U.S. board-certified physicians and licensed health care professionals.
During Telehealth Awareness Week, BlueCross will post telehealth information across its social media channels. Followers can expect topics such as explaining how a telehealth visit works, member testimonials and simplifying use of telehealth.
BlueCross and BlueChoice members can register for the service, which was launched in January 2016, at www.BlueCareOnDemandSC.com, or they can search for Blue CareOnDemand in the App Store or Google Play.
Many members have downloaded the app and those who have not are urged to do so now because of emergency uncertainties, including the upcoming flu season.
MUSC topped its record for annual biomedical research funding with more than $276 million in FY2018 see more
The Medical University of South Carolina has broken its own record as the state’s leader in garnering extramural funding for biomedical research. MUSC set a new high-water mark in FY2018, bringing in more than $276.5 million. The previous MUSC record for annual biomedical research funding was more than $259 million, set in FY2016.
“Being the state’s leader in biomedical research funding year after year is a significant accomplishment, and we applaud the passion and expertise of our dedicated scientists and their teams,” said David J. Cole, M.D., FACS, MUSC president. “Even so, reaching another record-breaking number is not an end in itself. The true impact of MUSC research is reflected in how we translate discoveries into new modalities of care and life-changing therapeutics. Research is a dynamic force that fuels how we fulfill our mission to lead health innovation for the lives we touch,” he added.
Kathleen Brady, M.D., Ph.D., vice president for Research, called the accomplishment outstanding, especially during a period when being awarded research grant funding has become more intensely competitive than ever before. No other publicly assisted academic institution in South Carolina consistently garners near $250 million in research funding year after year.
SCHA has awarded funds to two South Carolina universities to support healthcare programs see more
The S.C. Hospital Association has awarded the University of South Carolina and Clemson University $25,000 each to support the development of health care programs at the schools.
USC will use the gift to its Department of Health Services Policy and Management in the Arnold School of Public Health to support students in its master’s of health administration program, while Clemson will use the money to create interprofessional clinical learning opportunities in its School of Nursing’s partnership with Greenville Health System, according to a news release.
Additional funding may be provided after two years based on an annual review.
“The SCHA scholarship will help the MHA program as it prepares students for positions to advance the provision of effective, efficient and equitable health services in South Carolina,” said Bankole Olatosi, director of USC’s master’s of health administration program. “Our students will benefit from the increased access to professional education available through conferences, meetings and training to complement their education. Such opportunities will also be used as a marketing tool for recruiting more talented future health administrators to South Carolina.”
The scholarship program is funded by SCHA Solutions, a division of the hospital association that works with companies to provide services to state hospitals and health systems. Companies earn program endorsement by negotiating the best price for services and revenue sharing that support SCHA priorities, including workforce development.
“We're grateful for the South Carolina Hospital Association's support of our efforts to ensure that our graduates are well-prepared,” said Kathleen Valentine, Clemson School of Nursing director. “Through these funds, students will have increased access to experts in the fields of interprofessional teamwork, continuum of care, population health and community health. We want to make students aware of career opportunities within hospitals and in communities that extend the rich contributions nurses offer to patients and families and enable nurses to thrive within their professional role.”
Founded in 1921, Columbia-based SCHA advocates for the more than 70,000 workers employed in the state’s hospitals and health care systems.
“SCHA recently completed on-site meetings with leaders of every hospital in the state to learn more about their issues and challenges. Topping the list was recruiting and retaining a quality workforce,” said Lara Hewitt, SCHA Solutions vice president for workforce and partner engagement. “That makes it our priority, and we're pleased to be able to award these grants to help prepare the next generation of health care staff.”
Greenville Health System and Palmetto Health will come together under a single brand in 2019 see more
Greenville Health System and Palmetto Health will come together under a single brand, sharing a new name and logo, in early 2019.
As part of the new identity, the GHS, Palmetto Health and Palmetto Health-USC Medical Group brands, including their names and logos, will be retired. GHS and Palmetto Health will share a new purpose statement as well, which will replace current mission, vision and values statements. In addition, the interim name of the parent company, SC Health Company, will be replaced with the new name.
But much will remain the same:
· Patient care will always be the top priority for the organization. Together, GHS and Palmetto Health will continue to improve clinical quality, access to care and the patient experience, while also addressing rising health care costs.
· Both the affiliates will continue their unwavering commitment to the communities they’re privileged to serve.
· The organization’s commitment to transforming health care through education and research will not change. From educational and clinical research initiatives to collaborating with our academic partners, the organization remains strongly committed to academics. We will continue to focus on educating the next generation of medical providers and investing in clinical research to improve the lives of those we serve.
The new company name and logo will begin replacing the GHS and Palmetto Health names and logos in early 2019. However, campus and hospital names will retain their core name identities. Legacy hospital identities like Baptist, Greenville Memorial, Laurens, Richland and Tuomey will be included in the new names.
The Palmetto Health-USC Medical Group will change its name and logo in late 2019.
Coming together under one brand is a reflection of how GHS and Palmetto Health are focused on working together to improve the health of all South Carolinians. Both affiliates will continue to connect teams, tools, technology and education in an effort to make a lasting impact in the communities each has served for generations.
More information about the new brand identity, including the name, logo and purpose statement, will be announced Tuesday, Sept. 25.
Lou Kennedy, CEO Nephron Pharmaceuticals and Chair of the SCBIO Board, elected 2018-19 South Carolina Chamber ChairLou Kennedy, CEO of Nephron Pharmaceuticals, will chair the SC Chamber of Commerce Board for 2018-19 see more
The South Carolina Chamber of Commerce and the board have selected its newly elected officers and Board of Directors for 2018-2019. Leadership terms for the chamber’s officers and Board of Directors begin on October 1, 2018. Lou Kennedy will be the 2018 – 2019 Chairman.
Lou Kennedy is President, Chief Executive Officer and owner of Nephron Pharmaceuticals Corporation. She joined Nephron Pharmaceuticals in 2001 and accepted the position of President and Chief Executive Officer in September 2007. Along with her husband Bill, Kennedy helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy. She serves on a variety of business and civic boards.
Clemson partnership extends reach to India and beyond see more
Clemson University researchers said a new partnership with one of India’s top engineering universities will lead to new medical devices, sensors and startup companies, while helping educate leaders and entrepreneurs for the global healthcare industry.
Clemson is joining with the Indian Institute of Technology Delhi to create the Center for Innovative Medical Devices and Sensors.
The long-term vision for the center includes exchanges of faculty members, students and post-doctoral researchers, and to eventually establish joint courses. Some of the first projects will focus on solutions for diabetes and other chronic health issues common to both countries.
The first exchanges could begin as soon as next summer.
Researchers plan to focus on technology that is close to going from the lab to the marketplace, a concept that scholars call translational research. The devices that researchers develop could lead to biomedical start-ups — and the lucrative jobs that come with them– in South Carolina and India, they said.
An advantage to cross-border research is that new technology will be designed to meet regulatory requirements in multiple countries, smoothing the transition to markets around the globe, said Delphine Dean, who is the Gregg-Graniteville Associate Professor of Bioengineering at Clemson.
The collaboration is the latest in a growing number of links between South Carolina and India, a connection that could help build both economies, she said.
“If a company wants to have a landing base to do FDA testing, South Carolina is a great area to do it in,” she said. “We have a lot of resources at the state level, and I think it will help drive economic development. When you go visit IIT Delhi, they know Clemson, and they know South Carolina.”
Dean is coordinating the center with Sandeep K. Jha, an assistant professor in the Centre for Biomedical Engineering at IIT Delhi.
Jha said the joint center with Clemson will be a win-win for both institutions and that they will develop several vital technologies by working together.
“The research and continual development in the field of medical sensors and devices is the need of the hour,” he said. “Most of the conventional technology related to healthcare and diagnostics have gradually been shifted towards automation, miniaturization and cost-effectiveness.
“In this regard, a research collaboration with Clemson University to develop cutting-edge medical technology would be beneficial for India, as it imports the majority of its medical devices and technologies. Medical devices and sensors could also help to meet several critical needs of South Carolina.”
For Clemson students, the opportunity to visit labs and do research in India will encourage global-scale thinking.
“If I were an undergrad, I’d think this was a great opportunity,” Dean said. “You go enjoy an experience in India and then you get your engineering degree. Then you’re a hot commodity for a job.”
IIT Delhi students will be visiting Clemson primarily for research, graduate studies and specialized bioengineering programs. Those programs include the Master of Engineering program and Green MD, an initiative focused on medical device recycling and reprocessing.
One of the attractions for IIT Delhi students is that they will have a chance to work with Clemson faculty who have extensive experience in translational research, said Brij Khorana, the chief scientific advisor for the College of Engineering, Computing and Applied Sciences at Clemson.
“By working with these Clemson faculty members, they will have the opportunity to gain entrepreneurial skills and participate in start-up businesses here, and then perhaps some of these students can go back to India and help with the healthcare industry there,” Khorana said. “Over time, this collaboration can just grow and grow.”
Some of the students’ work will be on the main campus, and some will be in Greenville at the Clemson University Biomedical Engineering Innovation Campus. The campus, also called CUBEInC, is at Greenville Health System’s Patewood campus.
Clemson’s close connection with clinicians at GHS and Medical University of South Carolina will be appealing to IIT Delhi students, Dean said. Clinicians play a crucial role in guiding research, ensuring that it reflects what happens in real-world hospitals and clinics.
Martine LaBerge, chair of the Department of Bioengineering at Clemson, said the new center will create a unique environment for healthcare education and research.
“The Center for Innovative Medical Devices and Sensors sets the stage for integrative learning and inventing experiences,” LaBerge said. “Students will learn the leadership, entrepreneurial and technical skills they will need to support and enhance a knowledge-based economy.”
The collaboration between Clemson and IIT Delhi brings together two institutions noted for their work in engineering and healthcare.
IIT Delhi was the third highest ranked Indian university in the latest QS World University Rankings. The institute also tied for No. 1 in engineering among Indian universities in the annual “Performance Ranking of Scientific Papers for World Universities” by National Taiwan University.
Clemson is renowned as the birthplace of the field of biomaterials and was among the first universities in the United States to start a bioengineering program, awarding its first Ph.D. in 1963. The university played a central role in creating the Society for Biomaterials.
Anand Gramopadhye, dean of Clemson’s College of Engineering, Computing and Applied Sciences, said the center will enable transformative research and deepen the talent pool for the healthcare industry.
“By coming together, Clemson and IIT Delhi will be able to accomplish much more than we could apart,” he said. “We are creating the conditions for a wider pipeline between academia and industry, as well as a healthier global society.”
The Greenwood Genetic Center has named Richard Steet, PhD as Director of Research see more
GREENWOOD, South Carolina – The Greenwood Genetic Center has named Richard Steet, PhD as Director of Research and Head of the JC Self Research Institute. He joins the GGC faculty from the University of Georgia where he was Professor of Biochemistry and Molecular Biology in the University’s Complex Carbohydrate Research Center.
Steet’s research program, which is funded by the NIH and private foundations, is focused on defining disease mechanisms for two different classes of inherited diseases - lysosomal storage disorders and congenital disorders of glycosylation. Dr. Steet is also a dedicated advocate of rare disease research and serves on the scientific advisory boards for the National MPS Society and ISMRD, two organizations that provide family support and advance research.
“I am thrilled to become part of the world-renowned Greenwood Genetic Center, and I look forward to collaborating with their clinical and diagnostic divisions to enhance our understanding of the genetic basis for birth defects and disabilities,” said Steet.
Steet’s additional goals for the Center’s Research Division include integrating the Center’s strengths in basic science research with clinical and translational studies. He also plans to enhance partnerships with pharmaceutical companies that can drive therapeutic development for genetic disorders.
Steet and Heather Flanagan-Steet, PhD, who also joins GGC’s faculty as Director of Functional Studies and Director of the Center’s new Aquaculture Facility, study both cell and animal-based models of human disease. Their work uses a combination of chemical, molecular, and developmental approaches to unravel the complexity of these disorders and explore new ways to treat them. Their efforts will dovetail in many ways with the mission of the Clemson Center for Human Genetics, located adjacent to the JC Self Research Institute.
The Steets have been working with GGC over the past several months to set up a new aquaculture facility at the Center that, once fully operational, will house over 10,000 zebrafish. The facility, along with a new confocal microscope, which will arrive at GGC this fall, will allow in depth characterization of zebrafish models for several human genetic diseases. Their zebrafish and cell models will be further leveraged to study challenging cases seen in the clinic and diagnostic labs.
“Zebrafish, who share approximately 70% of their genes with humans, are a powerful model organism for genetic disorders,” shared Flanagan-Steet. “Since zebrafish embryos are clear, we can observe their development from the very beginning and learn how genetic factors lead to the disease-associated features that we see in patients.”
“GGC is fortunate to have the expertise of both Dr. Steet and Dr. Flanagan-Steet, and we are excited as our research program expands to include our first animal model,” said Steve Skinner, MD, Director of GGC. “The potential of this new area of study is tremendous, and what we learn through their lab will undoubtedly move us closer to developing effective treatments for patients with rare genetic disorders.”
Steet assumes the directorship from Charles Schwartz, PhD who joined GGC in 1985 as the Director of the Center’s Molecular Laboratory, and shifted his focus to lead research initiatives in 1996. Schwartz earned an international reputation in the area of X-linked intellectual disability. He remains on GGC faculty as a Senior Research Scientist.
State-of-the-art facility equipped with world-class labs, technologically advanced instrumentation see more
The Clemson Center for Human Genetics officially opened for business Tuesday evening, celebrating with an enthusiastic gathering of supporters who met with scientists and toured the state-of-the-art facility.
Piloted by a cadre of researchers equipped with world-class laboratories and technologically advanced instrumentation, Clemson’s Center for Human Genetics has successfully landed on the global stage – both in talent and scope. The center, which is part of Clemson’s College of Science, is dedicated to advancing knowledge of the fundamental principles by which genetic and environmental factors determine and predict healthy traits and susceptibility to disease.
The center is housed in Self Regional Hall with eight laboratories and several classrooms, conference rooms and offices for faculty and graduate students. The 17,000-square-foot building is located on the campus of the Greenwood Genetic Center. During Tuesday’s event, the labs and hallways were jammed with guests.
Trudy Mackay, director of the Center for Human Genetics, is recognized as one of the world’s leading authorities on the genetics of complex traits. Mackay, the Self Family Endowed Chair in Human Genetics and Professor of Genetics and Biochemistry, is a fellow of the American Association for the Advancement of Science. She has also been elected to the American Academy of Arts and Sciences, the Royal Society of London and the National Academy of Sciences.
Mackay is joined at Clemson by Robert Anholt, Provost’s Distinguished Professor of Genetics and Biochemistry and director of Faculty Excellence Initiatives in the College of Science. Anholt is also a member of the American Association for the Advancement of Science.
“This is an exciting time in the field of human genetics and its connection to health and well-being,” said Mackay, who has won numerous international awards, including the prestigious Wolf Prize, published more than 200 papers and trained graduate and postdoctoral students who have gone on to represent the next generation of geneticists. “We now know that all of us are 99.9 percent identical in our DNA, but that 10th of a percent difference translates to 3 million small genetic differences between any two of us. The challenge now is to understand how these molecular differences in DNA affect our susceptibility to diseases like cancer and heart ailments.”
Tuesday’s event was the culmination of 13 years of planning, collaboration and diligence. The naming of Self Regional Hall recognized the ongoing support from Self Regional Healthcare, which has contributed $5.6 million to the facility. In addition, the $4 million endowed chair held by Mackay was funded equally by the Self Family Foundation and the state of South Carolina.
“We are confident that our investment in the Self Family Endowed Chair for Human Genetics will pay huge dividends in furthering research to prevent, treat and cure genetic disorders,” said Frank Wideman, president of the Self Family Foundation. “We believe the synergy brought about by the intellectual capital of the Clemson Center for Human Genetics and that of the Greenwood Genetic Center has unlimited potential.”
Clemson University President James P. Clements praised the Self family, the city of Greenwood, Greenwood County, the Greenwood Commissioners of Public Works and the Greenwood Partnership Alliance for their generous support.
“Our partnership with the Greenwood Genetic Center, along with the amazing support we are receiving from Self Regional Healthcare and the Self Family Foundation, will allow our faculty researchers to translate their findings into tangible treatment options more quickly and efficiently,” Clements said. “The work being done here has the potential to make a huge difference in improving lives, which is at the core of Clemson’s mission as a land-grant university.”
Mackay and Anholt came to Clemson from North Carolina State, where they had conducted research for a combined 55 years. Most of Mackay’s new Clemson team also hail from N.C. State, including staff scientists Richard Lyman and Roberta Lyman, postdoctoral research associate Chad Highfill and doctoral students Brandon Baker and Sneha Mokashi. Rebecca Jones, who graduated with a bachelor’s degree in genetics from Clemson in May 2018, will be joining the team as a graduate student. Karl Kelly will continue to provide support as director of operations.
The Center for Human Genetics will work in partnership with the Greenwood Genetic Center, a nonprofit institute that focuses on clinical genetic services, diagnostic laboratory testing, educational programs and research. Mackay and her team will interact regularly with Greenwood Genetic Center personnel.
“This is an outstanding example of how the power of partnership can collectively harness talent to improve lives,” said Cynthia Y. Young, founding dean of Clemson’s College of Science. “Together, we have put a stake in the ground to develop a globally recognized center of excellence around human genetics anchored by some of the world’s most talented scientists.”
Dr. Steve Skinner, director of the Greenwood Genetic Center, said that the impact of the collaboration between the two centers will be transformative for genomics medicine.
“With the research expertise of Drs. Mackay and Anholt, and GGC’s illustrious history of providing clinical care and human genetics advancements, our combined efforts will advance the understanding of human diseases and behaviors, as well as guide us toward potential treatments to improve the quality of life for those impacted by neurodevelopmental and other genetic disorders.”
Skinner cited the recent joint acquisition of a NovaSeq 6000 DNA sequencer from Illumina as proof of the potency of the partnership.
“The NovaSeq is the most powerful sequencer available, and we have the only one in South Carolina,” Skinner said. “This instrument not only increases our DNA sequencing capacity and ability to diagnose complex patients though whole genome sequencing, it also provides genomic data to advance Clemson’s studies and GGC’s zebrafish models with the ultimate goal of improving patient health and quality of life.”
The main goals of the Center for Human Genetics include:
Leverage comprehensive genetic approaches and comparative genomics to explain the fundamental principles of human complex traits, including disease risk.
Promote precision medicine.
Develop local, regional, national and international collaborations to advance human genetics.
Educate the next generation of human geneticists.
Promote public understanding of human genetics through community outreach.
Much of the above will be accomplished by studying the inner workings of an insect that is smaller than a grain of rice. The fruit fly Drosophila melanogaster has turned out to be a remarkably powerful gene discovery system for large-scale, population-based genetic studies. About 70 percent of fly genes have human counterparts, which enable the construction of contextual genetic networks. Using the fly as their catalyst, Mackay and her team will seek new breakthroughs in the treatment of addiction, glaucoma, alcohol and fatty liver disease, oxidative stress, heavy metal toxicity, aging and neurological disorders.
“I am proud to lead Clemson’s Center for Human Genetics in Greenwood,” Mackay said. “We will have a strong connection to the main campus at Clemson to strengthen our research and academic core. Together with our partners, we will accomplish a great deal in the coming years.”
TSO3 to Commercialize the STERIZON VP4 Sterilizer and Support Getinge Transition see more
Myrtle Beach, United States and Quebec City, Canada August 1st, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices, today announced that TSO3 and a fund (the “Fund”) of which Courage Capital Management LLC, (“Courage”) is the investment advisor, have entered into a binding US$20 million debt financing to fund commercialization initiatives for its STERIZONE® VP4 Sterilizer, the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as certain colonoscopes, gastroscopes and duodenoscopes. Courage is a Nashville, TN headquartered alternative asset management firm with a 20-year track record of investments in health care services, medical devices, and pharmaceuticals.
Concurrent with the Courage financing, TSO3 and Getinge Infection Control AB (“Getinge”) mutually decided not to renew the distribution agreements between the parties, and have agreed to: 1) provide TSO3 unrestricted independent commercialization of its STERIZONE® VP4 Sterilizers; 2) the Company’s purchase of approximately 230 STERIZONE® VP4 Sterilizers, 220 of which are from Getinge’s inventory, for $33,000 per sterilizer; 3) transfer Getinge’s existing sales pipeline to TSO3 in exchange for shared economics at the completion of sale; and 4) transition to TSO3 the service, maintenance and consumables sales of all existing STERIZONE® VP4 Sterilizer customers in the United States and Canada. Getinge and TSO3 envision maintaining an ongoing collaborative relationship where TSO3 supplies and supports the STERIZONE® VP4 Sterilizer to satisfy Getinge customers looking for a total sterilization solution.
About the STERIZONE® VP4 Sterilizer
The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisturesensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error-free cycle selection. The device’s unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the 3 load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.
The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multichanneled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes, duodenoscopes and gastroscopes – an industry first for any medical device sterilization process.
The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).
More information about the STERIZONE® VP4 Sterilizer is available through TSO3‘s website, under the Products section.
Founded in 1998, TSO3‘s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
To read more about any of the following, please click here:
- Key Financing Terms with Courage
- The key financing terms of the transactions
- A Conference Call discussing these events
- Information on Courage Capital Management, LLC.
22 WESTEDGE BREAKS GROUND AND BREAKS THE MOLD FOR INNOVATIVE LIFE SCIENCES WORKPLACES IN CHARLESTON, SCNEW LIFE SCIENCES DISTRICT KICKS OFF CONSTRUCTION IN CHARLESTON, SC AT WESTEDGE see more
Charleston, SC - July 17, 2018 marked the construction kickoff for 22 WestEdge, a striking new workplace anchor for the city’s growing knowledge economy and the highly anticipated centerpiece of the WestEdge District. The iconic 125-foot, eight-story structure will be the tallest multi-tenant office building on the peninsula and in Charleston’s metropolitan area when it opens in November 2019.
“22 WestEdge affirms the vision for a Live, Learn and Earn district, adding vital office, research and lab components to the world class WestEdge community. It builds on the remarkable momentum of a development that already has over $300 million under construction,” said Michael Maher, CEO of The WestEdge Foundation, Inc., the non-profit sponsor of the overall development.
Even prior to the 22 WestEdge groundbreaking, area economic development proponents including The Medical University of South Carolina, the South Carolina Research Authority, the City of Charleston, Heritage Trust and the WestEdge Foundation committed to 22 WestEdge, forming the nucleus of entities working to incubate, attract and retain entrepreneurial talent to energize the Charleston economy. While 48% of the space is currently leased, 72,000 square feet of office space and 10,000 square feet of retail space remain available for existing local businesses, or for new companies being created or relocating to the Charleston region. This is a remarkable concentration of ingenuity¾over 35,000 people live, work, study and seek healthcare expertise in the adjacent medical district.
Partnership and innovation opportunities abound for 22 WestEdge tenants—with unprecedented access to like-minded neighbors and colleagues in Charleston’s life sciences sector. Dr. David Cole, President of MUSC shared, “With MUSC’s $275 million of research and proprietary discoveries, 22 WestEdge will allow the University to collaborate with private industry to create new healthcare solutions, new companies and recruit existing global medical-related companies to Charleston.” Bob Quinn, Executive Director of the SCRA agreed, “SCRA’s leasing of the entire top floor of 22 WestEdge will allow us to create a world-class facility, including laboratories, which will serve as a catalyst for the attraction of leading life sciences companies and the creation of a Discovery District adjacent to MUSC.”
Charleston Mayor John Tecklenburg echoed, “It’s no secret that biomedical advances will be a key driver of our economy and society in the years ahead. With 156,000 square feet of office space dedicated to precisely the kind of research and enterprise that will help make those breakthroughs possible, 22 WestEdge is a welcome and important addition to our city’s medical district.”
22 WestEdge office tenants will also benefit from the energy and vitality of the district. Recently completed, The Caroline has 237 apartments and 20,000 square feet of retail and restaurant space, and the topped-out 10 WestEdge will have 350 residential units, a Publix Super Market, Woodhouse Spa and additional retail and restaurant space, providing an abundance of shopping, eating and living options for all. 22 WestEdge’s own amenities include 15,000 square feet of cafes and fitness facilities, common conference and event facilities and a terrace wrapping the 7th floor with sweeping views of the Ashley River. Mack Reese, 22 WestEdge developer and partner, explains his reason for developing the project, “With its access to parking, numerous retail amenities and an urban density of residential opportunities for employees, the building will be a new and exciting option for existing Charleston businesses and those looking to relocate to the region.”
Upon completion, WestEdge’s master-planned mixed-use district will encompass more than 3,000,000 square feet of space on 60 acres along the Ashley River adjacent to MUSC and the Medical District, and fronting on Brittlebank Park and the Joseph Riley Baseball Stadium. WestEdge is a public-private partnership created to advance economic development and expand the research capabilities of the Medical University of South Carolina and foster new companies and collaborative opportunities with private industry. It is an innovative redevelopment that is transforming the quality of life for Charleston’s west side.
Key 22 WestEdge partners include Gateway Development (Developer) ELV Associates (Investor), BB&T (Lender), Trident Construction (General Contractor), Perkins & Will (Architect), Thomas and Hutton (Civil Engineer), and Lee & Associates (Marketing & Leasing).
For leasing inquiries and further detail on WestEdge development, please contact Mack Reese of Gateway Development (770-310-3414 ).
MUSC receives grant for expansion of telehealth program see more
The Medical University of South Carolina (MUSC) palliative care program has received a $1,278,000 grant from The Duke Endowment to create a statewide, palliative care telehealth program.
Providing end of life and comfort care to those in need, especially for the state’s most vulnerable and rural populations, is the primary aim of the new effort. Program leadership expects not only an improvement to accessibility for this kind of care, but also potential cost savings to individual patients and the system as a whole. Click for full details.
Moterum selected to present at prestigious medtech conference in Chicago, IL see more
Southeastern medtech company develops mobility solutions for patients suffering from strokes, neural traumas; forum convenes investors seeking leading-edge advances in health and life sciences
GREENVILLE, S.C. – July 11, 2018 – Moterum Technologies Inc., a South Carolina-based mobility and gait rehabilitation development company, has been selected to present at the prestigious Cavendish BioHealth Impact Forum July 17-18, 2018 in Chicago, Illinois. The Forum provides an environment for organizations and investors to further their strategic social impact investing, grant-giving, and philanthropy programs in support of health and life sciences advances.
Co-hosted by Cavendish Global, the Shirley Ryan AbilityLab, and MATTER, the Forum showcases presentations and panel discussions by leading research institutions, private-sector companies, nonprofit organizations, and foundations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.
Moterum Technologies is one of 10 featured organizations invited to present their solutions at the Chicago Conference. An innovative medical technology development company, Moterum’s focus is designed to help resolve mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients how to re-learn walking in their own home.
“We are honored to be selected to present at the 2018 Chicago Forum, and value the recognition it will provide of our innovative approach to helping stroke survivors walk independently and without a limp or asymmetry,” said David Huizenga, CEO of Moterum Technologies. “Our device can be used at home and is fully connected and positioned for telehealth systems, making it a viable solution for developed and developing health systems alike. We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to improving the health and lives of people around the world.”
The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, and seeks to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.
“With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said J. Michael Moffat, Chairman of Cavendish Global. “The quality and originality of Moterum Technologies’ research and scientific insights in treating gait problems of stroke survivors positions them to make a major contribution to global health by helping stroke survivors retake an independent position in society.”
For further information on Moterum Technologies, visit www.moterum.com.
About Moterum Technologies Inc.
Moterum Technologies is an innovative medical technology development company that focuses on solving mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients to relearn how to walk in their own home.